

Company announcement no. 08 2009/10

20 April 2010

The American Health Care Authorities (Food and Drug Administration-FDA) have cleared Ambu's single-use videoscope, Ambu[®] aScope[™]

Ambu has been granted the 510K clearance for the Ambu[®] aScope[™] by the American health care authorities. The Ambu[®] aScope[™] consists of two parts, the single-use videoscope and a monitor.

With this clearance, the products, which were launched in the European market around New Year 2009, can now be launched, marketed and sold in the American market.

Further information:

Lars Marcher, CEO, phone +45 5136 2490, e-mail: lm@ambu.com

Ambu develops, produces and markets diagnostic and life-supporting devices to hospitals and rescue services. Ambu has three business areas: Airway Management, Patient Monitoring & Diagnostics and Emergency Care. The primary products are ventilation products for artificial respiration and electrodes for ECG recordings and neurophysiological examinations as well as manikins for first-aid training. Ambu's products are marketed worldwide. Exports account for 98% of revenue, and sales are handled via Ambu's foreign subsidiaries or via distributors. Ambu has approx. 1,600 employees, of whom 300 work in Denmark and 1,300 abroad.